Cargando…
Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens.
The effect of clodronate on bone mineral density (BMD) was studied in 121 post-menopausal breast cancer women without skeletal metastases. In addition, two antioestrogens, tamoxifen and toremifene, were compared in their action on bone mineral density. Patients were randomized to have an adjuvant an...
Autores principales: | Saarto, T., Blomqvist, C., Välimäki, M., Mäkelä, P., Sarna, S., Elomaa, I. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group|1
1997
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063321/ https://www.ncbi.nlm.nih.gov/pubmed/9052418 |
Ejemplares similares
-
The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer
por: Saarto, T, et al.
Publicado: (2001) -
Aminoterminal propeptide of type I procollagen (PINP) correlates to bone loss and predicts the efficacy of antiresorptive therapy in pre- and post-menopausal non-metastatic breast cancer patients.
por: Saarto, T., et al.
Publicado: (1998) -
Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer.
por: Saarto, T., et al.
Publicado: (1997) -
Non-Steroidal Antioestrogens
por: Barnes, D.
Publicado: (1983) -
Plasma Fluoride Level and Femoral Bone Mineral Density in Post-Menopausal Women
por: Santhanam, Prasanna, et al.
Publicado: (2016)